Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $15.39 Consensus Target Price from Brokerages

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have received a consensus recommendation of “Hold” from the thirteen analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $15.3889.

FOLD has been the topic of several analyst reports. Leerink Partners lowered shares of Amicus Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $17.00 to $14.50 in a research report on Monday, December 29th. Citigroup restated a “neutral” rating and set a $14.50 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Monday, December 22nd. Jefferies Financial Group reaffirmed a “hold” rating and issued a $14.50 target price (down from $16.00) on shares of Amicus Therapeutics in a report on Thursday, January 22nd. TD Cowen lowered Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price target on the stock. in a research note on Monday, December 22nd. Finally, Zacks Research cut Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 26th.

Amicus Therapeutics Stock Down 0.1%

FOLD stock opened at $14.45 on Friday. The company has a market cap of $4.54 billion, a PE ratio of -180.63 and a beta of 0.48. The business has a 50-day simple moving average of $14.38 and a 200 day simple moving average of $12.22. Amicus Therapeutics has a 52 week low of $5.51 and a 52 week high of $14.48. The company has a quick ratio of 1.88, a current ratio of 2.84 and a debt-to-equity ratio of 1.43.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.The firm had revenue of $185.21 million for the quarter, compared to analyst estimates of $185.00 million. During the same quarter in the previous year, the company earned $0.09 earnings per share. The company’s quarterly revenue was up 23.7% on a year-over-year basis. Sell-side analysts anticipate that Amicus Therapeutics will post 0.15 EPS for the current fiscal year.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 75,000 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $14.31, for a total transaction of $1,073,250.00. Following the completion of the transaction, the chief executive officer owned 1,021,180 shares of the company’s stock, valued at approximately $14,613,085.80. The trade was a 6.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amicus Therapeutics

A number of hedge funds have recently made changes to their positions in FOLD. Ion Asset Management Ltd. bought a new stake in shares of Amicus Therapeutics during the third quarter worth $6,875,000. Elevation Point Wealth Partners LLC bought a new position in shares of Amicus Therapeutics in the 3rd quarter valued at $2,961,000. CIBRA Capital Ltd bought a new position in shares of Amicus Therapeutics in the 4th quarter valued at $3,002,000. Nordea Investment Management AB acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at $7,843,000. Finally, Principal Financial Group Inc. boosted its holdings in shares of Amicus Therapeutics by 1,229.5% during the 3rd quarter. Principal Financial Group Inc. now owns 263,325 shares of the biopharmaceutical company’s stock valued at $2,075,000 after acquiring an additional 243,519 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.